Chapter 7: Hypertension — Clinical and Pharmacological Series — Module: HTN-02 — Diagnosis, Evaluation, and Secondary Causes Tier: Tier 4
CASE 1
Mr. R.T. is a 54-year-old man referred for resistant hypertension. His BP is 168/102 mmHg on lisinopril 40 mg, amlodipine 10 mg, and chlorthalidone 25 mg, with confirmed adherence by pill count and pharmacy refill records. He has no edema. Serum potassium is 3.2 mEq/L. Creatinine is 1.1 mg/dL. He does not take NSAIDs or other BP-elevating agents. He does not snore and has no witnessed apneas.
1. [CASE 1 — QUESTION 1]
Based on Mr. R.T.'s clinical presentation, which of the following is the most appropriate next step in his evaluation?
A) Measure plasma aldosterone concentration and plasma renin activity to calculate the aldosterone-to-renin ratio (ARR) — the combination of resistant hypertension and unprovoked hypokalemia of 3.2 mEq/L on chlorthalidone makes primary aldosteronism the leading diagnosis requiring biochemical screening
B) Add a fourth antihypertensive agent empirically — resistant hypertension on three agents with confirmed adherence warrants intensification before any secondary cause workup
C) Order a renal artery duplex ultrasound as the first test — resistant hypertension in a middle-aged man should prompt renovascular evaluation before endocrine workup
D) Order a 24-hour urine catecholamines and metanephrines — episodic symptoms are not required for pheochromocytoma screening in resistant hypertension and this should be the first test ordered
E) Perform overnight polysomnography — obstructive sleep apnea is the most common cause of resistant hypertension and should be excluded before any other workup
ANSWER: A
Rationale:
The combination of resistant hypertension on three appropriately selected agents with confirmed adherence and unprovoked hypokalemia of 3.2 mEq/L is the classic presentation of primary aldosteronism (PA); PA is the most common endocrine cause of secondary hypertension, found in approximately 5–20% of resistant hypertension cases; the aldosterone-to-renin ratio is the recommended first-line screening test.
Option B: Option B is incorrect — empirical intensification without secondary cause workup in a patient with unprovoked hypokalemia and resistant hypertension is inappropriate; a treatable cause should be identified first.
Option C: Option C is incorrect — renovascular hypertension is a reasonable consideration but the unprovoked hypokalemia specifically points toward PA as the leading diagnosis; ARR is the appropriate first test here.
Option D: Option D is incorrect — plasma metanephrines (not 24-hour urine) are the preferred initial pheochromocytoma screening test in most guidelines, and this is not the leading diagnosis given the hypokalemia and absence of episodic symptoms.
Option E: Option E is incorrect — OSA is common in resistant hypertension but the unprovoked hypokalemia specifically directs the workup toward PA first.
2. [CASE 1 — QUESTION 2]
Mr. R.T.'s ARR returns at 42 with plasma aldosterone 24 ng/dL and plasma renin activity 0.57 ng/mL/hr. A saline infusion test is performed: post-infusion aldosterone is 9.8 ng/dL (normal suppression threshold <5 ng/dL), confirming autonomous aldosterone secretion. CT adrenal imaging shows a 1.8 cm left adrenal adenoma and a normal right adrenal gland. Which of the following most accurately describes the appropriate next step before definitive treatment?
A) The CT findings of a unilateral left adrenal adenoma with confirmed biochemical PA are sufficient to proceed directly to left laparoscopic adrenalectomy — CT localization alone is adequate for surgical planning in PA
B) Repeat CT imaging with adrenal protocol in 6 months is required before any further workup because a single CT is insufficient to characterize adrenal adenomas less than 2 cm
C) The saline infusion test result of 9.8 ng/dL is below 10 ng/dL and therefore represents adequate suppression, meaning the PA diagnosis has not been confirmed and no further workup is needed
D) Medical management with spironolactone should be started immediately without AVS because the CT adenoma is visible and AVS adds procedural risk without changing management in a patient with a clear CT finding
E) Adrenal vein sampling (AVS) should be performed to confirm lateralization of aldosterone excess to the left adrenal gland before surgery — CT imaging in PA has a false localization rate of approximately 20–40% because contralateral microadenomas and bilateral hyperplasia can mimic unilateral adenoma on CT; AVS is the gold standard for confirming surgical candidacy
ANSWER: E
Rationale:
AVS is the gold standard for confirming lateralization of aldosterone excess before adrenalectomy in PA; CT imaging has a false localization rate of 20–40% in PA — contralateral microadenomas, bilateral hyperplasia, and non-functioning adenomas on the wrong side can all produce misleading CT findings; proceeding to adrenalectomy based on CT alone risks removing the wrong gland or operating on a patient with bilateral disease who would not benefit from surgery.
Option A: Option A is incorrect — CT localization alone is insufficient; AVS is required to confirm surgical candidacy and correct lateralization.
Option C: Option C is incorrect — the standard suppression threshold for the saline infusion test is <5 ng/dL; a post-infusion aldosterone of 9.8 ng/dL confirms failure of suppression and confirms autonomous aldosterone secretion; the PA diagnosis is confirmed.
Option D: Option D is incorrect — while spironolactone is appropriate medical management, bypassing AVS in a surgical candidate foregoes the possibility of cure through adrenalectomy, which is the preferred treatment for unilateral PA; AVS changes management in a clinically significant proportion of patients.
Option B: Option B is incorrect — repeat CT is not the appropriate next step; AVS, not repeat imaging, is the required confirmatory test for lateralization.
3. [CASE 1 — QUESTION 3]
AVS confirms left-sided lateralization with a lateralization index of 6.2 (threshold >2 for lateralization). Mr. R.T. elects surgery. While awaiting adrenalectomy, his potassium is 3.0 mEq/L and BP remains 162/98 mmHg. Which of the following most accurately describes the pharmacological preparation for surgery?
A) No pharmacological changes are needed before surgery — the existing three-drug regimen should be continued unchanged until the morning of surgery and potassium supplementation is not required because it will normalize after adrenalectomy
B) Fludrocortisone should be added to correct the hypokalemia by promoting sodium retention and secondarily increasing potassium reabsorption in the collecting duct
C) Lisinopril should be discontinued before surgery because ACE inhibitors are contraindicated in the perioperative period for adrenalectomy due to risk of intraoperative hypotension from aldosterone withdrawal
D) Spironolactone should be initiated as a bridge to surgery to control BP and correct hypokalemia through mineralocorticoid receptor blockade — this addresses both the autonomous aldosterone excess and the hypokalemia; potassium levels should be rechecked 2–4 weeks after initiation; oral potassium supplementation may be added if needed while awaiting spironolactone effect
E) Bilateral adrenal blockade with metyrapone should be initiated before unilateral adrenalectomy to prevent contralateral adrenal insufficiency from the surgical stress response
ANSWER: D
Rationale:
Spironolactone is the appropriate pharmacological bridge to adrenalectomy in PA — it blocks the mineralocorticoid receptor, directly addressing the autonomous aldosterone effect on collecting duct sodium reabsorption and potassium wasting; it corrects hypokalemia and helps control BP preoperatively; potassium monitoring and supplementation may be needed in the early weeks before full spironolactone effect is established.
Option A: Option A is incorrect — leaving potassium at 3.0 mEq/L without intervention is inappropriate; hypokalemia at this level carries risk of cardiac arrhythmia and should be corrected before surgery; spironolactone is specifically indicated.
Option C: Option C is incorrect — ACE inhibitors are not contraindicated perioperatively for adrenalectomy; there is no specific indication to discontinue lisinopril; the concern about perioperative hypotension is managed through anesthetic management, not preoperative ACE inhibitor discontinuation in this context.
Option B: Option B is incorrect — fludrocortisone is a synthetic mineralocorticoid; adding it to a patient with mineralocorticoid excess from PA would profoundly worsen hypertension and hypokalemia.
Option E: Option E is incorrect — metyrapone blocks cortisol synthesis and is used in Cushing syndrome, not in PA; bilateral adrenal blockade is not indicated before unilateral adrenalectomy for PA.
4. [CASE 1 — QUESTION 4]
Mr. R.T. undergoes successful left laparoscopic adrenalectomy. On postoperative day 2 his potassium is 4.6 mEq/L and BP is 138/86 mmHg on his original three-drug regimen. His spironolactone has been stopped. Over the following 6 weeks his BP gradually normalizes to 124/78 mmHg and he is able to discontinue chlorthalidone and reduce lisinopril to 10 mg. Which of the following most accurately explains why his BP improvement may be incomplete and some antihypertensive therapy may still be required long-term?
A) The adrenalectomy was incomplete — residual adenoma tissue always remains after laparoscopic surgery and requires a second surgical procedure to achieve full BP normalization
B) His remaining antihypertensives are causing rebound hypertension through compensatory neurohormonal activation that would resolve if all medications were stopped simultaneously
C) Long-standing aldosterone excess causes structural vascular changes including arterial wall remodeling, increased vascular stiffness, and target organ damage that do not fully reverse after aldosterone normalization; additionally, some patients with PA have underlying essential hypertension that is unmasked once the aldosterone-driven component is removed; complete BP normalization without any medication occurs in only approximately 35–50% of patients after adrenalectomy
D) The contralateral adrenal gland has undergone compensatory hyperplasia during the period of unilateral aldosterone excess and is now secreting excess aldosterone independently, requiring spironolactone to be restarted permanently
E) Lisinopril should be discontinued entirely because ACE inhibition is no longer needed once the primary aldosteronism is cured and continued use will cause hypotension through unopposed renin activity in the now-normalized RAAS
ANSWER: C
Rationale:
Complete BP normalization after adrenalectomy for unilateral PA occurs in approximately 35–50% of patients; the remainder have partial improvement but require ongoing antihypertensive therapy; the explanation is multifactorial — long-standing aldosterone excess causes irreversible structural vascular changes including arterial wall fibrosis, increased stiffness, and end-organ damage that do not fully reverse with aldosterone normalization; additionally, some patients have concurrent essential hypertension that is unmasked when the aldosterone-driven component is removed; younger patients with shorter duration of hypertension and less target organ damage have the best rates of complete cure.
Option A: Option A is incorrect — residual adenoma after laparoscopic adrenalectomy is not the standard explanation for incomplete BP response; the vascular and structural changes of chronic aldosterone excess are the primary mechanism.
Option B: Option B is incorrect — rebound hypertension from stopping antihypertensives simultaneously is not the explanation; gradual de-escalation as tolerated is appropriate and the persistent BP reflects residual vascular disease.
Option D: Option D is incorrect — contralateral adrenal hyperplasia from unilateral excess is not established; suppression of the contralateral gland is more typical because chronic autonomous aldosterone secretion suppresses the renin-angiotensin system that normally drives the contralateral gland.
Option E: Option E is incorrect — continued RAAS inhibition with lisinopril is appropriate in a patient with residual hypertension; the clinical decision to continue or taper is based on BP response, not a blanket rule against ACE inhibitors after PA cure.
CASE 2
Ms. P.V. is a 38-year-old woman referred for evaluation of episodic hypertension. She describes recurring episodes of severe headache, diaphoresis, and palpitations lasting 15–30 minutes occurring 2–3 times per week, often triggered by bending over or emotional stress. Between episodes her BP is 138/86 mmHg. During an episode captured in the emergency department her BP was 218/124 mmHg and HR was 118 bpm. She has no family history of endocrine tumors. BMI is 23. Thyroid function is normal.
5. [CASE 2 — QUESTION 1]
Which of the following is the most appropriate initial biochemical test to evaluate Ms. P.V. for pheochromocytoma?
A) 24-hour urine catecholamines (epinephrine, norepinephrine, dopamine) — urine catecholamines are the gold standard first-line test for pheochromocytoma with superior sensitivity to plasma metanephrines
B) Serum chromogranin A — this neuroendocrine tumor marker is the recommended first-line test for pheochromocytoma because it reflects total tumor secretory activity
C) Plasma free metanephrines (metanephrine and normetanephrine) — these are the O-methylated metabolites of epinephrine and norepinephrine produced continuously within the tumor regardless of episodic secretion, providing superior sensitivity compared to spot catecholamine measurements that may miss inter-episode samples
D) Random urine metanephrines collected during an episode — episodic pheochromocytoma can only be diagnosed biochemically if the sample is collected during a hypertensive crisis; between-episode testing is unreliable and should not be attempted
E) Clonidine suppression test — clonidine suppresses catecholamine release in essential hypertension but fails to suppress in pheochromocytoma, making it the most specific first-line test for this diagnosis
ANSWER: C
Rationale:
Plasma free metanephrines (metanephrine and normetanephrine) are the recommended first-line biochemical test for pheochromocytoma per Endocrine Society guidelines — they have the highest sensitivity (approximately 96–99%) because metanephrines are produced continuously within the tumor by intratumoral COMT (catechol-O-methyltransferase) regardless of whether the tumor is actively secreting catecholamines at the time of sampling; this means even episodic tumors with inter-episode testing will be detected.
Option A: Option A is incorrect — 24-hour urine catecholamines have lower sensitivity than plasma metanephrines because catecholamine secretion is episodic; the 24-hour collection may miss the secretory peaks; urine metanephrines (not urine catecholamines) have better diagnostic utility but plasma metanephrines remain the preferred first-line test.
Option B: Option B is incorrect — chromogranin A is a general neuroendocrine tumor marker with insufficient specificity for pheochromocytoma screening as a first-line test; it is elevated in many neuroendocrine tumors and has false positives with PPI use.
Option D: Option D is incorrect — plasma free metanephrines can detect pheochromocytoma between episodes due to continuous intratumoral metanephrine production; waiting for an episode to collect samples is unnecessary and delays diagnosis.
Option E: Option E is incorrect — the clonidine suppression test is a confirmatory test used when plasma metanephrines are borderline elevated, not a first-line screening test; it adds procedural complexity inappropriate as an initial step.
6. [CASE 2 — QUESTION 2]
Ms. P.V.'s plasma free metanephrines return markedly elevated: metanephrine 3.4 nmol/L (normal <0.5 nmol/L) and normetanephrine 8.7 nmol/L (normal <0.9 nmol/L). CT abdomen and pelvis shows a 4.2 cm right adrenal mass with heterogeneous enhancement. Surgery is planned. Which of the following most accurately describes the required pharmacological preparation before adrenalectomy?
A) Beta-blockade with metoprolol should be initiated first to control her heart rate of 118 bpm and prevent intraoperative tachycardia before any other pharmacological intervention
B) Alpha-blockade must be established first — phenoxybenzamine (a non-selective irreversible alpha blocker) or a selective alpha-1 blocker such as doxazosin should be initiated at least 10–14 days before surgery to prevent the hypertensive crisis that occurs when surgical manipulation of the tumor releases massive catecholamines; beta-blockade may be added only after adequate alpha-blockade is established to control reflex tachycardia
C) No pharmacological preparation is required before adrenalectomy for pheochromocytoma — modern laparoscopic technique and intraoperative anesthetic management are sufficient to prevent hypertensive crisis without preoperative alpha-blockade
D) Combined alpha and beta blockade should be initiated simultaneously on the same day — the sequence of alpha before beta is a historical teaching that has been disproven in modern practice; simultaneous initiation achieves faster control
E) Metyrosine (alpha-methyl-p-tyrosine), a tyrosine hydroxylase inhibitor that blocks catecholamine synthesis, should be the sole preoperative agent — it depletes tumor catecholamine stores more effectively than receptor blockade and eliminates the need for alpha or beta blockers
ANSWER: B
Rationale:
Alpha-blockade must precede beta-blockade in pheochromocytoma surgical preparation — this is a non-negotiable pharmacological sequence; surgical manipulation of the tumor causes massive catecholamine release; without prior alpha-blockade, this produces life-threatening hypertensive crisis; phenoxybenzamine (non-selective, irreversible) or selective alpha-1 blockers (doxazosin, prazosin) are initiated 10–14 days preoperatively; beta-blockade is added only after alpha-blockade is established to manage reflex tachycardia; starting beta-blockade first blocks the compensatory vasodilatory beta-2 effect while leaving alpha-1 vasoconstriction unopposed, which can precipitate a hypertensive crisis.
Option A: Option A is incorrect — initiating beta-blockade before alpha-blockade in pheochromocytoma is specifically contraindicated; blocking beta-2 mediated vasodilation while leaving alpha-1 vasoconstriction unopposed dramatically worsens hypertension and can be fatal.
Option C: Option C is incorrect — pharmacological alpha-blockade before surgery is the standard of care; intraoperative management alone is insufficient to prevent the hemodynamic instability caused by surgical tumor manipulation without prior receptor blockade.
Option D: Option D is incorrect — simultaneous initiation risks the unopposed alpha-vasoconstriction problem described above; the sequence is physiologically determined, not historical convention.
Option E: Option E is incorrect — metyrosine is occasionally used as an adjunct to reduce tumor catecholamine stores but is not used as a sole preoperative agent; alpha-blockade remains the cornerstone of preoperative preparation.
7. [CASE 2 — QUESTION 3]
Ms. P.V. is started on phenoxybenzamine, titrated over 2 weeks. She develops orthostatic hypotension with a standing BP drop of 28 mmHg and feels lightheaded when rising. Her surgeon is concerned. Which of the following most accurately explains why this orthostatic hypotension is expected and how it should be managed?
A) Orthostatic hypotension from phenoxybenzamine reflects successful alpha-1 blockade reversing the chronic alpha-mediated vasoconstriction that has been maintaining her BP — the intravascular volume contracted by chronic catecholamine excess is now unmasked; management includes high sodium diet, liberal fluid intake, and compression stockings rather than dose reduction; a degree of orthostatic hypotension is an expected and acceptable finding confirming adequate preoperative alpha-blockade
B) The orthostatic hypotension indicates phenoxybenzamine overdose and the dose should be immediately halved to prevent syncopal falls before surgery
C) The orthostatic hypotension is caused by phenoxybenzamine's beta-blocking properties producing a negative chronotropic response to standing that prevents the compensatory tachycardia required to maintain BP on position change
D) Phenoxybenzamine should be switched to a selective alpha-1 blocker such as doxazosin because selective agents do not cause orthostatic hypotension through the presynaptic alpha-2 blockade mechanism that phenoxybenzamine produces
E) Fludrocortisone should be added to increase intravascular volume and reverse the orthostatic hypotension through mineralocorticoid-mediated sodium retention — this is the standard pharmacological treatment for phenoxybenzamine-induced orthostasis
ANSWER: A
Rationale:
Orthostatic hypotension during phenoxybenzamine preparation for pheochromocytoma surgery is an expected and desirable finding — it confirms that alpha-1 blockade is adequate and that the chronic catecholamine-driven vasoconstriction is being relieved; chronic catecholamine excess causes intravascular volume contraction (patients are effectively volume-depleted despite hypertension); as alpha-blockade reverses vasoconstriction, the relative volume depletion becomes apparent as orthostatic hypotension; the standard management is high sodium diet, increased fluid intake, and compression stockings to expand intravascular volume — not dose reduction, which would leave inadequate protection for surgery.
Option B: Option B is incorrect — orthostatic hypotension is an expected finding indicating successful blockade, not overdose; dose reduction risks inadequate preoperative preparation.
Option C: Option C is incorrect — phenoxybenzamine is an alpha-adrenergic blocker, not a beta-blocker; it does not cause negative chronotropy; reflex tachycardia is actually a common effect of alpha-blockade.
Option D: Option D is incorrect — while selective alpha-1 blockers do cause less orthostatic hypotension than phenoxybenzamine (which also blocks presynaptic alpha-2 receptors, preventing compensatory norepinephrine release and worsening orthostasis), switching agents is not indicated simply because expected orthostasis has developed; the orthostasis is managed conservatively.
Option E: Option E is incorrect — fludrocortisone is not the standard treatment for phenoxybenzamine-induced orthostasis; high sodium diet and fluid loading are the appropriate interventions.
8. [CASE 2 — QUESTION 4]
Ms. P.V. undergoes successful right adrenalectomy. Intraoperatively, BP peaked at 196/112 mmHg during tumor manipulation and was controlled with IV nitroprusside, then dropped to 88/54 mmHg after tumor ligation and was managed with IV fluids and norepinephrine infusion. Postoperatively on day 1 her BP is 102/64 mmHg and she remains on a low-dose norepinephrine infusion. Plasma metanephrines collected on postoperative day 3 are normal. Which of the following most accurately explains the postoperative hypotension and guides its management?
A) The postoperative hypotension is caused by residual phenoxybenzamine effect — phenoxybenzamine's irreversible alpha-1 blockade persists for the lifespan of the receptor (approximately 24 hours per receptor cohort) and the accumulated blockade from 2 weeks of therapy takes 7–10 days to fully reverse
B) The postoperative hypotension reflects adrenal insufficiency from removal of the cortisol-producing adrenal cortex along with the medullary tumor — hydrocortisone replacement must be initiated immediately to prevent adrenal crisis
C) The postoperative hypotension results from the abrupt loss of the tumor's catecholamine secretion combined with the volume depletion of surgery — the vasomotor tone that maintained her BP was largely catecholamine-dependent; the remaining adrenal medulla and sympathetic nervous system require days to weeks to upregulate baseline catecholamine output; management includes IV fluid resuscitation, temporary vasopressor support, and gradual weaning as endogenous sympathetic tone recovers
D) The hypotension indicates that the wrong adrenal gland was removed — contralateral pheochromocytoma is now the dominant source of catecholamines and a second operation is required urgently
E) The postoperative norepinephrine infusion should be stopped immediately because exogenous catecholamine administration after pheochromocytoma resection causes receptor downregulation that permanently impairs the recovery of endogenous vasomotor tone
ANSWER: C
Rationale:
Postoperative hypotension after pheochromocytoma resection is a well-recognized and expected phenomenon — the tumor has been providing sustained high-level catecholamine stimulation that maintained vascular tone and BP; upon tumor removal, this catecholamine source is abruptly eliminated; the contralateral adrenal medulla and sympathetic nervous system are relatively suppressed by chronic catecholamine excess and require time (days to weeks) to restore normal output; management is supportive with IV fluids and temporary vasopressor support with gradual weaning; normal plasma metanephrines on day 3 confirm complete resection.
Option A: Option A is incorrect — while phenoxybenzamine's irreversible blockade does contribute to postoperative vasodilation, it is not the primary or sole explanation; the abrupt loss of tumor-derived catecholamine tone is the dominant mechanism; the 24-hour receptor turnover concept is correct but phenoxybenzamine's contribution resolves within 1–3 days.
Option B: Option B is incorrect — laparoscopic adrenalectomy for a medullary tumor preserves the adrenal cortex in most cases; adrenal cortical insufficiency is not expected unless total adrenalectomy was performed or bilateral disease is present; the contralateral adrenal cortex also provides cortisol reserve.
Option D: Option D is incorrect — normal plasma metanephrines on postoperative day 3 confirm biochemical cure and correct resection; postoperative hypotension is expected and explained by catecholamine withdrawal, not a missed contralateral tumor.
Option E: Option E is incorrect — temporary vasopressor support with norepinephrine is appropriate management for postoperative hypotension after pheochromocytoma resection; there is no evidence that short-term exogenous catecholamine use permanently impairs endogenous vasomotor recovery.
CASE 3
Mr. D.K. is a 67-year-old man with longstanding hypertension and peripheral arterial disease who presents with sudden onset pulmonary edema requiring ICU admission. His BP on arrival is 198/110 mmHg. He was started on lisinopril 5 mg 3 weeks ago by his cardiologist. His creatinine on admission is 3.1 mg/dL; his baseline creatinine 6 weeks ago was 1.4 mg/dL. He has an abdominal bruit. His echocardiogram shows preserved EF of 60% with no wall motion abnormalities.
9. [CASE 3 — QUESTION 1]
Which of the following most accurately identifies the unifying diagnosis explaining Mr. D.K.'s presentation?
A) He has hypertensive emergency with acute pulmonary edema from diastolic dysfunction — the preserved EF confirms HFpEF as the etiology and the creatinine rise is from reduced renal perfusion secondary to low cardiac output
B) He has unilateral right renal artery stenosis — the abdominal bruit and peripheral arterial disease point to this diagnosis; unilateral RAS causes the same acute creatinine rise after ACE inhibitor initiation as bilateral RAS because the contralateral kidney cannot compensate
C) He has ACE inhibitor-induced angioedema causing laryngeal obstruction with secondary pulmonary edema and the creatinine rise reflects acute tubular necrosis from hypoxia
D) He has bilateral renal artery stenosis presenting as flash pulmonary edema — the acute creatinine rise of 1.7 mg/dL following ACE inhibitor initiation, the abdominal bruit, the history of peripheral arterial disease (indicating diffuse atherosclerosis), and the flash pulmonary edema with preserved EF in the absence of primary cardiac pathology are the classic constellation of bilateral hemodynamically significant renal artery stenosis; ACE inhibitor initiation in bilateral RAS removes the efferent arteriolar tone that was maintaining GFR in both kidneys, precipitating acute kidney injury
E) He has contrast nephropathy from a recent imaging procedure causing AKI and the flash pulmonary edema reflects fluid overload from anuric acute kidney injury
ANSWER: D
Rationale:
The clinical constellation is diagnostic of bilateral renal artery stenosis — flash pulmonary edema with preserved EF (indicating the lungs filled acutely without primary systolic dysfunction), acute creatinine rise of 1.7 mg/dL within 3 weeks of ACE inhibitor initiation, an abdominal bruit, and peripheral arterial disease indicating diffuse atherosclerosis are the hallmarks; in bilateral RAS, glomerular filtration in both kidneys is maintained by angiotensin II-mediated efferent arteriolar constriction; ACE inhibitor removes this efferent constriction, causing bilateral GFR collapse and acute kidney injury; the resulting inability to excrete sodium and water precipitates flash pulmonary edema.
Option A: Option A is incorrect — while HFpEF can cause flash pulmonary edema, the acute creatinine rise after ACE inhibitor initiation and the abdominal bruit together identify a specific secondary cause that must not be missed; HFpEF does not explain the creatinine rise pattern.
Option C: Option C is incorrect — ACE inhibitor angioedema involves the airway (larynx, tongue, lips) and does not cause pulmonary edema through airway obstruction; the creatinine rise pattern is not consistent with hypoxic ATN.
Option B: Option B is incorrect — unilateral RAS does not cause the same ACE inhibitor-induced AKI as bilateral RAS; in unilateral RAS, the contralateral kidney maintains overall GFR; a 1.7 mg/dL creatinine rise is not expected from unilateral disease.
Option E: Option E is incorrect — no contrast administration is mentioned; this history is not consistent with contrast nephropathy.
10. [CASE 3 — QUESTION 2]
Lisinopril is discontinued and Mr. D.K.'s creatinine returns to 1.6 mg/dL over 5 days with IV diuresis. MRA (magnetic resonance angiography) of the renal arteries confirms bilateral renal artery stenosis — 80% on the right and 75% on the left. His cardiologist, nephrologist, and interventional radiologist discuss management. Which of the following most accurately describes the evidence basis for the management decision?
A) Bilateral renal artery angioplasty with stenting should be performed immediately because revascularization in bilateral RAS always restores renal function to baseline and prevents future flash pulmonary edema episodes
B) Medical management alone with antihypertensives other than ACE inhibitors or ARBs is the appropriate approach — the ASTRAL and CORAL trials demonstrated that renal artery stenting did not provide benefit over medical therapy alone in terms of renal function, BP control, or cardiovascular events in most patients with atherosclerotic RAS; however, bilateral RAS with recurrent flash pulmonary edema is a specific clinical scenario where revascularization may be considered because medical management alone cannot prevent the hemodynamic consequences of bilateral outflow obstruction
C) ACE inhibitors should be restarted at a lower dose because the initial dose of 5 mg was too high; bilateral RAS is not a contraindication to ACE inhibitors at lower doses
D) ARBs are the preferred antihypertensive for bilateral RAS because they block angiotensin II at the receptor level rather than preventing its formation, allowing residual efferent arteriolar tone to be maintained while still controlling BP
E) Surgical renal artery bypass is the only effective treatment for bilateral atherosclerotic RAS in a 67-year-old with peripheral arterial disease — endovascular stenting is contraindicated in diffuse atherosclerosis
ANSWER: B
Rationale:
The ASTRAL (Angioplasty and Stenting for Renal Artery Lesions) and CORAL (Cardiovascular Outcomes in Renal Atherosclerotic Lesions) trials established that renal artery stenting did not provide meaningful benefit over optimized medical therapy alone in atherosclerotic RAS for most endpoints including renal function and BP; however, both trials excluded or had limited numbers of patients with bilateral RAS and recurrent flash pulmonary edema — this specific clinical scenario (bilateral RAS with flash pulmonary edema) is widely considered a potential indication for revascularization because the episodic pulmonary edema represents a hemodynamic consequence of bilateral outflow obstruction that cannot be fully addressed by medical therapy alone.
Option A: Option A is incorrect — revascularization does not always restore renal function; outcomes depend on degree of ischemic nephropathy already present; and the ASTRAL/CORAL data argue against routine stenting for most indications.
Option C: Option C is incorrect — ACE inhibitors and ARBs are specifically contraindicated in bilateral RAS because both remove efferent arteriolar tone in both kidneys simultaneously, causing bilateral GFR collapse; this is not dose-dependent.
Option D: Option D is incorrect — ARBs carry the same contraindication as ACE inhibitors in bilateral RAS; both classes block the RAAS effect on efferent arteriolar tone regardless of whether blockade is at the level of ACE or the AT1 receptor.
Option E: Option E is incorrect — surgical bypass is not the only option; endovascular stenting is the primary revascularization modality in atherosclerotic RAS when intervention is indicated.
11. [CASE 3 — QUESTION 3]
The team decides on medical management given Mr. D.K.'s high surgical risk and the ASTRAL/CORAL evidence. His BP needs to be controlled without ACE inhibitors or ARBs. His current creatinine is 1.6 mg/dL and he has 2+ pitting edema. Which of the following represents the most pharmacologically sound antihypertensive regimen for this patient?
A) Amlodipine plus a thiazide diuretic — calcium channel blockers are safe in bilateral RAS and thiazides provide volume control; this two-drug combination is sufficient for most patients
B) Spironolactone as the primary agent — mineralocorticoid receptor antagonism provides BP control and is specifically renoprotective in atherosclerotic RAS through reduction of aldosterone-mediated renal fibrosis
C) Clonidine as the primary agent — central alpha-2 agonists are uniquely safe in bilateral RAS because they reduce BP through central sympatholysis without any renal vascular effects
D) Hydralazine as a direct vasodilator should be the primary agent because direct smooth muscle relaxation lowers BP without RAAS involvement and does not affect renal autoregulation in the stenotic segment
E) A loop diuretic for volume management combined with amlodipine for BP control and either a beta-blocker or a non-dihydropyridine CCB for additional BP reduction if needed — ACE inhibitors and ARBs must be avoided; with creatinine of 1.6 mg/dL and 2+ edema, a loop diuretic is preferred over a thiazide; this regimen addresses both volume overload (a major contributor to flash pulmonary edema in bilateral RAS) and BP through agents that do not compromise GFR through efferent arteriolar dilation
ANSWER: E
Rationale:
In bilateral RAS without ACE inhibitors or ARBs, the pharmacological strategy addresses the two main contributors to morbidity — volume overload (which precipitates flash pulmonary edema) and systemic hypertension; with creatinine of 1.6 mg/dL, a loop diuretic (furosemide or torsemide) is preferred over thiazides for volume control given the reduced GFR; amlodipine (dihydropyridine CCB) is safe in RAS and provides BP lowering; beta-blockers or additional agents can be added for further BP control; this regimen avoids the efferent arteriolar dilation of RAAS inhibitors while addressing both pathological mechanisms.
Option A: Option A is incorrect — thiazides lose efficacy at this level of renal impairment; a loop diuretic is the appropriate choice for volume control with creatinine of 1.6 mg/dL and significant edema.
Option C: Option C is incorrect — while clonidine is safe in bilateral RAS, it is not uniquely superior or preferred as a primary agent; rebound hypertension with missed doses is a significant limitation; it does not address the volume overload component that drives flash pulmonary edema.
Option D: Option D is incorrect — hydralazine causes reflex tachycardia and fluid retention requiring concurrent beta-blocker and diuretic; it is not a preferred primary agent in modern hypertension management and does not address the volume component.
Option B: Option B is incorrect — while spironolactone has some benefit in resistant hypertension, it is not specifically indicated as the primary agent in bilateral RAS and at this level of renal impairment carries significant hyperkalemia risk.
12. [CASE 3 — QUESTION 4]
Mr. D.K. is discharged on furosemide 40 mg daily, amlodipine 10 mg, and metoprolol succinate 50 mg. At 3-month follow-up his BP is 144/88 mmHg and creatinine is stable at 1.7 mg/dL. He has had no further pulmonary edema episodes. His cardiologist wants to optimize his regimen and asks about the role of statin therapy and antiplatelet agents in his management. Which of the following most accurately describes their role?
A) Statins and antiplatelet agents have no role in renovascular hypertension management — they are cardiac medications not applicable to renal vascular disease
B) Statin therapy is indicated for his atherosclerotic renal artery disease as part of cardiovascular risk reduction — atherosclerotic RAS is a manifestation of systemic atherosclerosis and statin therapy slows progression of atherosclerotic disease; antiplatelet therapy with low-dose aspirin is similarly indicated as secondary prevention given his peripheral arterial disease and atherosclerotic RAS; these are not curative for RAS but address the underlying atherosclerotic process driving his vascular disease burden
C) High-intensity statin therapy should be initiated to reverse the renal artery stenosis — statins have been shown in randomized trials to reduce atherosclerotic plaque burden in renal arteries and restore normal luminal diameter within 12 months
D) Antiplatelet therapy is contraindicated in bilateral RAS because platelet inhibition worsens the ischemic injury to the kidney by impairing the microthrombus formation that partially maintains renal perfusion in the stenotic segment
E) Statin therapy should be withheld because his creatinine of 1.7 mg/dL represents a contraindication to statin use — statin-induced rhabdomyolysis risk is prohibitively high in CKD stage 3
ANSWER: B
Rationale:
Atherosclerotic renal artery stenosis is a manifestation of systemic atherosclerosis — the same pathological process driving his peripheral arterial disease; statin therapy is indicated for cardiovascular risk reduction and atherosclerosis management in this patient regardless of the RAS; antiplatelet therapy (low-dose aspirin or clopidogrel) is standard secondary prevention in established atherosclerotic vascular disease including peripheral arterial disease; together these agents address the systemic atherosclerotic burden, reduce cardiovascular event risk, and may slow progression of atherosclerotic stenosis, though they do not reverse established hemodynamically significant lesions.
Option A: Option A is incorrect — statins and antiplatelet agents are clearly indicated in atherosclerotic vascular disease including RAS; they are not limited to cardiac applications.
Option C: Option C is incorrect — statins do not reverse established atherosclerotic renal artery stenosis or restore normal luminal diameter within 12 months; they slow progression and reduce cardiovascular events but are not curative for established hemodynamic stenosis.
Option D: Option D is incorrect — antiplatelet therapy does not worsen ischemic renal injury; it reduces atherosclerotic plaque rupture and thrombotic events; there is no evidence that platelet inhibition is harmful in RAS.
Option E: Option E is incorrect — CKD stage 3 is not a contraindication to statin therapy; statins are used in CKD and the cardiovascular benefit is maintained; rhabdomyolysis risk requires dose adjustment in severe CKD but is not a contraindication at creatinine 1.7 mg/dL.
CASE 4
Ms. L.F. is a 52-year-old woman referred for resistant hypertension. Her BP is 158/96 mmHg on amlodipine 10 mg and lisinopril 40 mg with confirmed adherence. Her BMI is 36. Her husband reports that she snores loudly and has witnessed apneas. She is excessively sleepy during the day and fell asleep during her last physician visit. Epworth Sleepiness Scale score is 16 out of 24. ARR, plasma metanephrines, and renal artery imaging are normal. Her potassium is 4.1 mEq/L.
13. [CASE 4 — QUESTION 1]
Which of the following most accurately describes the relationship between obstructive sleep apnea and hypertension in Ms. L.F.?
A) OSA causes hypertension only through the mechanical effect of increased intrathoracic pressure during apneic episodes; the relationship is purely hemodynamic and resolves immediately when apneas are eliminated
B) OSA is the most common identifiable cause of secondary hypertension; the mechanism is multifactorial — each apneic episode causes intermittent hypoxia, hypercapnia, and arousal which activate the sympathetic nervous system; chronic sympathetic overactivation causes sustained increases in systemic vascular resistance and BP even during waking hours; aldosterone dysregulation, endothelial dysfunction, and rostral fluid shift in the supine position all contribute; her clinical features (obesity, witnessed apneas, excessive daytime somnolence, Epworth score 16) are highly consistent with severe OSA as a significant contributor to her resistant hypertension
C) OSA causes hypertension only during sleep — daytime BP is determined entirely by other factors; treatment of OSA with CPAP normalizes nighttime BP but has no effect on daytime or office BP readings
D) The relationship between OSA and hypertension is confined to non-dippers — patients with OSA who show normal nocturnal BP dipping have no OSA-mediated contribution to their hypertension and CPAP treatment would not benefit their BP
E) OSA causes hypertension exclusively through aldosterone excess from intermittent hypoxia stimulating adrenal aldosterone secretion; this is why mineralocorticoid receptor antagonists are the specific pharmacological treatment for OSA-related hypertension independent of CPAP
ANSWER: B
Rationale:
OSA is widely recognized as the most common identifiable cause of secondary hypertension; the pathophysiology is multifactorial — intermittent hypoxia and hypercapnia during apneic episodes activate peripheral chemoreceptors and the sympathetic nervous system; repeated overnight arousals sustain sympathetic tone; chronic sympathetic overactivation raises systemic vascular resistance and BP during both sleep and waking hours; aldosterone dysregulation (partly through overnight fluid shifts and hypoxia-mediated adrenal stimulation) and endothelial dysfunction also contribute; her clinical features strongly suggest severe OSA requiring polysomnography.
Option A: Option A is incorrect — the mechanism involves chronic neurohormonal activation, not just acute intrathoracic pressure changes; daytime sympathetic tone is persistently elevated and does not resolve immediately.
Option C: Option C is incorrect — CPAP therapy for OSA does reduce daytime and office BP, though the effect size is modest (approximately 2–3 mmHg mean reduction); the OSA-mediated sympathetic activation affects 24-hour BP, not only nocturnal BP.
Option D: Option D is incorrect — while non-dipping is more prevalent in OSA, daytime BP is also affected through the mechanisms described; CPAP benefit is not confined to dippers.
Option E: Option E is incorrect — aldosterone dysregulation is one contributor among several; OSA-related hypertension is not exclusively aldosterone-mediated and mineralocorticoid receptor antagonists are not the specific treatment; CPAP is the primary therapy.
14. [CASE 4 — QUESTION 2]
Polysomnography confirms severe OSA with AHI (apnea-hypopnea index) of 48 events/hour. Ms. L.F. is initiated on CPAP therapy and achieves good adherence (>6 hours/night). At 3-month follow-up her daytime somnolence has resolved. Her BP is now 148/92 mmHg — improved but still above target. Which of the following most accurately guides the next pharmacological step?
A) CPAP alone should be continued for another 6 months without medication change — the full antihypertensive effect of CPAP takes 12 months to manifest and adding medications before this timeframe is premature
B) The incomplete BP response confirms that OSA was not contributing to her hypertension — CPAP should be discontinued and the full resistant hypertension workup should be repeated from the beginning
C) CPAP has provided a meaningful but incomplete BP response, which is expected — the average BP reduction with CPAP in resistant hypertension is modest (2–4 mmHg systolic); a third antihypertensive agent is now appropriate; spironolactone is specifically supported by evidence in resistant hypertension and addresses the aldosterone dysregulation component of OSA-related hypertension; her potassium of 4.1 mEq/L and normal renal function make spironolactone safe to initiate
D) Clonidine should be added as the third agent because central sympatholysis specifically targets the sympathetic overactivation mechanism of OSA-related hypertension and is superior to all other third-line agents in this setting
E) The amlodipine dose should be reduced now that CPAP is established because the combination of CPAP and maximum-dose amlodipine will cause excessive BP lowering and the total antihypertensive load must be decreased before adding a third agent
ANSWER: C
Rationale:
CPAP produces a real but modest antihypertensive effect — average reductions of 2–4 mmHg systolic in most trials of resistant hypertension with OSA; a BP of 148/92 mmHg on two agents after CPAP still warrants a third agent; spironolactone has specific evidence in resistant hypertension (PATHWAY-2 trial — spironolactone vs placebo in resistant hypertension demonstrating superior BP reduction as a fourth agent) and addresses the aldosterone dysregulation that is common in both OSA and resistant hypertension; with potassium 4.1 mEq/L and no renal impairment described, it is safe to initiate.
Option A: Option A is incorrect — the full antihypertensive effect of CPAP does not require 12 months; meaningful BP effects are seen within weeks to months; delaying pharmacological optimization for 12 months is clinically inappropriate.
Option B: Option B is incorrect — a 10 mmHg systolic reduction (from 158 to 148) with CPAP is a meaningful response consistent with OSA contribution; it does not exclude OSA as a contributor; resistant hypertension rarely resolves completely with any single intervention.
Option D: Option D is incorrect — while clonidine does target sympathetic overactivation, it is not evidence-based as specifically superior to spironolactone in OSA-related resistant hypertension; its side effect profile (sedation, rebound hypertension) and the strong evidence for spironolactone make it a less appropriate choice here.
Option E: Option E is incorrect — reducing a well-tolerated agent that is part of a rational regimen before adding a third agent is not the appropriate approach; the combination of CPAP and amlodipine has not caused excessive BP lowering.
15. [CASE 4 — QUESTION 3]
Spironolactone 25 mg is added. At 6 weeks her BP is 132/82 mmHg and potassium is 5.3 mEq/L. She complains of breast tenderness and irregular menstrual cycles. Which of the following most accurately addresses her anti-androgenic side effects and guides management?
A) Spironolactone's anti-androgenic effects (gynecomastia in men, breast tenderness and menstrual irregularity in women) result from its non-selective binding to androgen, progesterone, and glucocorticoid receptors in addition to the mineralocorticoid receptor — eplerenone is a selective mineralocorticoid receptor antagonist that does not bind androgen or progesterone receptors and lacks these off-target effects; switching to eplerenone at an equivalent dose preserves the antihypertensive and antialdosterone benefit while eliminating the anti-androgenic side effects
B) The anti-androgenic side effects of spironolactone are permanent and irreversible — spironolactone should be discontinued and a non-mineralocorticoid agent substituted regardless of its BP efficacy
C) The potassium of 5.3 mEq/L is a more urgent concern than the anti-androgenic side effects and spironolactone should be discontinued immediately for hyperkalemia management before addressing the hormonal complaints
D) The breast tenderness and menstrual irregularity are unrelated to spironolactone and represent a coincidental new gynecological issue requiring separate evaluation; spironolactone should be continued unchanged
E) The dose of spironolactone should be increased to 50 mg to achieve better BP control before considering a switch to eplerenone — higher doses are required to see full mineralocorticoid receptor selectivity that minimizes anti-androgenic effects
ANSWER: A
Rationale:
Spironolactone's anti-androgenic side effects result from its non-selective receptor binding profile — it binds not only the mineralocorticoid receptor but also androgen and progesterone receptors; in women this causes breast tenderness, menstrual irregularity, and occasionally amenorrhea; in men it causes gynecomastia and sexual dysfunction; eplerenone is a selective mineralocorticoid receptor antagonist that does not bind androgen or progesterone receptors, eliminating these off-target effects; switching to eplerenone at an equivalent antihypertensive dose is the appropriate management when anti-androgenic side effects are limiting spironolactone therapy; her BP response has been excellent and the mineralocorticoid antagonism should be preserved.
Option B: Option B is incorrect — the side effects are dose-dependent and reversible upon discontinuation or switching; they are not permanent; switching to eplerenone rather than abandoning mineralocorticoid receptor antagonism altogether is the appropriate response.
Option C: Option C is incorrect — a potassium of 5.3 mEq/L warrants monitoring and dietary counseling but does not require immediate spironolactone discontinuation; it is elevated but not in the dangerous range (>6.0 mEq/L) and should be rechecked; it is not more urgent than the quality-of-life affecting hormonal side effects that are the patient's primary complaint.
Option D: Option D is incorrect — breast tenderness and menstrual irregularity are well-recognized and common side effects of spironolactone in premenopausal women; attributing them to a coincidental gynecological issue is inappropriate without excluding the drug as the cause.
Option E: Option E is incorrect — higher doses of spironolactone increase anti-androgenic side effects, not reduce them; the solution is to switch to the selective agent eplerenone, not to increase the non-selective agent.
16. [CASE 4 — QUESTION 4]
Ms. L.F. is switched to eplerenone 50 mg. Her hormonal symptoms resolve within 6 weeks. At 6-month follow-up on CPAP, amlodipine 10 mg, lisinopril 40 mg, and eplerenone 50 mg her BP is 128/78 mmHg and potassium is 4.9 mEq/L. She asks whether she can stop CPAP now that her BP is controlled on medications. Which of the following most accurately addresses her question?
A) She can discontinue CPAP because her BP is now controlled on medications — the CPAP was needed only to enable pharmacological control and once that is achieved the device is no longer necessary
B) CPAP should be continued indefinitely — OSA is a chronic condition with consequences beyond hypertension including increased risk of atrial fibrillation, stroke, motor vehicle accidents from daytime somnolence, metabolic syndrome, and cardiovascular mortality; CPAP treats the underlying disorder, not just the BP; discontinuing CPAP would likely cause return of somnolence, worsening of BP control, and re-exposure to the cardiovascular consequences of repeated nocturnal hypoxia and sympathetic activation; weight loss is the only intervention that can potentially reduce OSA severity enough to eliminate CPAP need
C) CPAP can be discontinued during summer months when upper airway inflammation from seasonal allergies worsens OSA severity, and resumed in winter when OSA naturally improves
D) CPAP discontinuation is appropriate if she achieves a BMI below 30 through weight loss — OSA is entirely caused by obesity and resolves completely with normalization of BMI regardless of the original AHI
E) The decision to continue CPAP should be based on repeat polysomnography off CPAP — if the AHI on repeat testing is below 15 events/hour she can discontinue CPAP because mild OSA does not contribute meaningfully to cardiovascular risk
ANSWER: B
Rationale:
OSA is a chronic disorder with multisystem consequences extending well beyond BP — untreated OSA is associated with increased risk of atrial fibrillation, stroke, heart failure, metabolic syndrome, motor vehicle accidents from daytime somnolence, and cardiovascular mortality; CPAP treats the underlying physiological disorder (repeated nocturnal hypoxia, arousal, and sympathetic activation), not merely a surrogate marker; discontinuing CPAP would predictably cause recurrence of somnolence, worsening of BP control through loss of the antihypertensive contribution, and re-exposure to the cardiovascular risks of severe OSA; weight loss can reduce AHI significantly and in some patients with obesity-driven OSA, sufficient weight loss may reduce AHI enough to eliminate CPAP need — but this should be guided by repeat polysomnography after sustained weight loss, not by BP response alone.
Option A: Option A is incorrect — BP control on medications does not address the non-hypertensive cardiovascular consequences of OSA; CPAP treats the disorder itself.
Option C: Option C is incorrect — OSA severity does not reliably vary seasonally in a clinically meaningful way; this is not a basis for intermittent CPAP use.
Option D: Option D is incorrect — while obesity is the most important modifiable risk factor for OSA, AHI does not uniformly normalize with weight loss to BMI <30; structural airway anatomy also contributes; repeat polysomnography after weight loss is required to confirm resolution.
Option E: Option E is incorrect — an AHI of 15 events/hour (moderate OSA) is not clinically benign; it carries significant cardiovascular risk and would still warrant treatment; the threshold for clinically significant OSA requiring treatment is generally AHI ≥5 with symptoms or ≥15 regardless of symptoms.
CASE 5
Ms. C.B. is a 44-year-old woman referred for hypertension evaluation. Her BP is 162/98 mmHg. She has gained 18 kg over the past 18 months despite no change in diet or activity. She has new-onset type 2 diabetes with HbA1c 8.2%. She has facial plethora, a dorsocervical fat pad, and wide purple striae on her abdomen. Her potassium is 3.1 mEq/L. She has been taking no exogenous steroids. Her 24-hour urinary free cortisol is 4.2 times the upper limit of normal.
17. [CASE 5 — QUESTION 1]
Which of the following most accurately describes the mechanism by which cortisol excess causes hypertension in Ms. C.B.?
A) Cortisol causes hypertension exclusively through sodium retention mediated by direct mineralocorticoid receptor activation — cortisol has identical affinity for the mineralocorticoid receptor as aldosterone at physiological concentrations
B) The hypertension in Cushing syndrome is caused entirely by the obesity and insulin resistance that accompany cortisol excess — cortisol itself has no direct vascular or renal effect on BP
C) Cortisol causes hypertension only through glucocorticoid receptor-mediated effects on cardiac output — the mineralocorticoid pathway is not involved in Cushing syndrome because the kidneys have efficient 11β-HSD2 activity that prevents any cortisol from reaching mineralocorticoid receptors regardless of cortisol concentration
D) Cortisol excess causes hypertension through multiple complementary mechanisms — at supraphysiological concentrations, cortisol overcomes the renal 11-beta-hydroxysteroid dehydrogenase type 2 (11β-HSD2) enzyme that normally converts cortisol to inactive cortisone before it reaches the mineralocorticoid receptor; this allows cortisol to directly activate mineralocorticoid receptors causing sodium retention and potassium wasting; additionally, cortisol upregulates angiotensinogen production, increases vascular sensitivity to catecholamines, and causes direct glucocorticoid receptor-mediated cardiovascular effects; the hypokalemia of 3.1 mEq/L in this patient reflects the mineralocorticoid activity of excess cortisol
E) Cortisol causes hypertension through adrenal androgen excess — the elevated androgens from the adrenal gland cause peripheral vasoconstriction through androgen receptor-mediated smooth muscle activation
ANSWER: D
Rationale:
Cortisol causes hypertension through multiple mechanisms — the 11β-HSD2 enzyme in renal tubular cells normally protects the mineralocorticoid receptor from cortisol by converting it to cortisone; at supraphysiological concentrations, cortisol overwhelms this enzymatic protection and directly activates mineralocorticoid receptors, causing sodium retention, potassium wasting (explaining the hypokalemia of 3.1 mEq/L), and volume expansion; additionally, cortisol increases angiotensinogen synthesis (raising angiotensin II levels), increases vascular sensitivity to norepinephrine and angiotensin II through upregulation of their receptors, and has direct glucocorticoid receptor-mediated cardiovascular effects; the result is multimechanistic hypertension.
Option A: Option A is incorrect — cortisol does not have identical affinity for the mineralocorticoid receptor as aldosterone at physiological concentrations; 11β-HSD2 normally prevents cortisol-mineralocorticoid receptor interaction; the problem in Cushing syndrome is overwhelming the enzyme at supraphysiological concentrations.
Option C: Option C is incorrect — 11β-HSD2 is overwhelmed at supraphysiological cortisol levels; mineralocorticoid receptor activation by cortisol is a central mechanism of Cushing syndrome hypertension; the mineralocorticoid pathway is not intact when cortisol is markedly elevated.
Option B: Option B is incorrect — cortisol has direct vascular and renal effects on BP independent of obesity; these mechanisms explain why hypertension in Cushing syndrome often requires specific pharmacological management beyond lifestyle modification.
Option E: Option E is incorrect — adrenal androgen excess is not the mechanism of hypertension in Cushing syndrome; the cortisol itself and its downstream effects on mineralocorticoid receptors and vascular physiology are responsible.
18. [CASE 5 — QUESTION 2]
Pituitary MRI shows a 6 mm ACTH-secreting adenoma consistent with Cushing disease. Transsphenoidal surgery is planned. While awaiting surgery, her BP is 168/104 mmHg and potassium is 2.9 mEq/L. Which of the following most accurately describes the pharmacological approach to cortisol excess control during the surgical waiting period?
A) Spironolactone alone is sufficient as a bridge to surgery — blocking the mineralocorticoid receptor will correct both the hypokalemia and hypertension without the need for steroidogenesis inhibitors
B) Ketoconazole or metyrapone can be used as steroidogenesis inhibitors to reduce cortisol production during the preoperative period — ketoconazole inhibits multiple cytochrome P450 enzymes involved in adrenal steroidogenesis (including CYP11A1, CYP11B1, and CYP17A1) and effectively lowers cortisol; metyrapone inhibits 11β-hydroxylase (CYP11B1), the final step in cortisol synthesis; either agent can bridge to surgery, controlling the metabolic and cardiovascular consequences of hypercortisolemia while the surgical date approaches; potassium supplementation and antihypertensive therapy may still be needed during the bridging period
C) High-dose dexamethasone should be given to suppress ACTH secretion from the pituitary adenoma through negative feedback — dexamethasone is the preferred glucocorticoid for suppression therapy in Cushing disease
D) Mifepristone (RU-486) should be initiated because glucocorticoid receptor blockade is the most effective way to control cortisol excess in Cushing disease and does not require cortisol level monitoring
E) No pharmacological intervention is needed before surgery — Cushing disease of short duration (18 months) does not require preoperative cortisol control because the metabolic consequences are fully reversible after tumor resection without interim pharmacological management
ANSWER: B
Rationale:
Steroidogenesis inhibitors are the pharmacological bridge to surgery in Cushing disease — ketoconazole inhibits multiple adrenal cytochrome P450 enzymes reducing cortisol synthesis and has been used for decades in this indication; metyrapone specifically inhibits CYP11B1 (11β-hydroxylase), the final step in cortisol synthesis, and is effective and relatively fast-acting; both agents reduce cortisol production and improve the metabolic and cardiovascular consequences of hypercortisolemia preoperatively; cortisol levels and clinical response must be monitored; additional antihypertensives and potassium supplementation are typically still needed during bridging.
Option A: Option A is incorrect — spironolactone addresses the mineralocorticoid consequences of cortisol excess but does not reduce cortisol levels; it does not address the glucocorticoid receptor-mediated cardiovascular and metabolic effects of hypercortisolemia; it is appropriate as an adjunct but not as sole management.
Option C: Option C is incorrect — dexamethasone does not suppress ACTH from a pituitary adenoma causing Cushing disease; the adenoma is autonomous and resistant to normal glucocorticoid negative feedback; dexamethasone suppression tests exploit this resistance diagnostically.
Option D: Option D is incorrect — mifepristone blocks the glucocorticoid receptor but does not reduce cortisol levels; cortisol rises further due to lost negative feedback; monitoring cortisol levels becomes uninformative; it is used in Cushing syndrome with hyperglycemia as a specific indication but is not the preferred first-line preoperative agent.
Option E: Option E is incorrect — 18 months of significant hypercortisolemia with hypokalemia, poorly controlled hypertension, and diabetes warrants active preoperative management to reduce surgical risk and metabolic burden.
19. [CASE 5 — QUESTION 3]
Ms. C.B. undergoes successful transsphenoidal resection. On postoperative day 1 her morning cortisol is undetectable (<1 mcg/dL). She is started on hydrocortisone replacement. Over the following 3 months her BP gradually normalizes to 118/74 mmHg, she loses 9 kg, her HbA1c improves to 6.8%, and her potassium normalizes. At 6 months her hydrocortisone dose is being tapered. Which of the following most accurately describes the expected course of her adrenal axis and the clinical significance of the postoperative undetectable cortisol?
A) The undetectable postoperative cortisol indicates that both adrenal glands were inadvertently removed during the pituitary surgery and permanent primary adrenal insufficiency requiring lifelong mineralocorticoid and glucocorticoid replacement has resulted
B) The undetectable cortisol indicates recurrent disease — the adenoma has already returned and is now secreting ACTH in excess causing paradoxical adrenal suppression through a negative feedback mechanism unique to recurrent pituitary adenomas
C) The undetectable cortisol is expected in all postoperative patients regardless of surgical outcome — it reflects the effect of anesthetic agents on adrenal function and normalizes within 48 hours without hydrocortisone supplementation
D) The undetectable postoperative cortisol confirms surgical cure — the long-standing ACTH excess from the adenoma has suppressed the normal corticotroph cells of the anterior pituitary through prolonged negative feedback; after adenoma removal, the normal corticotrophs require months to recover function; during this recovery period the patient is dependent on exogenous hydrocortisone and must be counseled on sick-day rules and stress dosing; recovery of the hypothalamic-pituitary-adrenal axis typically takes 6–18 months and is confirmed by stimulation testing
E) The patient should be switched from hydrocortisone to dexamethasone for replacement because dexamethasone has a longer half-life and provides more stable cortisol coverage during the HPA axis recovery period
ANSWER: D
Rationale:
Undetectable postoperative cortisol is the gold standard biochemical marker of surgical cure in Cushing disease — it confirms complete removal of the ACTH-secreting adenoma; the normal corticotroph cells of the anterior pituitary are suppressed because they have been chronically inhibited by the adenoma's autonomous ACTH production and the resulting hypercortisolemia; after adenoma removal, these suppressed corticotrophs require months (typically 6–18 months) to recover normal function; during this period the patient is cortisol-dependent and requires hydrocortisone replacement with stress dosing for illness, surgery, or physiological stress; HPA axis recovery is confirmed by morning cortisol or ACTH stimulation testing during the taper process.
Option A: Option A is incorrect — the adrenal glands are not involved in transsphenoidal pituitary surgery; the undetectable cortisol reflects corticotroph suppression, not adrenal removal; primary adrenal insufficiency from bilateral adrenalectomy has a different clinical and biochemical profile.
Option C: Option C is incorrect — anesthetic agents do not cause undetectable cortisol lasting beyond hours; an undetectable postoperative cortisol in this context specifically reflects surgical cure with corticotroph suppression.
Option B: Option B is incorrect — undetectable cortisol in the immediate postoperative period indicates successful removal of the ACTH source, not recurrence; recurrence would produce rising ACTH and cortisol levels.
Option E: Option E is incorrect — dexamethasone is not appropriate for physiological replacement because it does not provide the mineralocorticoid activity of hydrocortisone, suppresses the HPA axis more profoundly, and its potency makes accurate physiological replacement dosing more difficult; hydrocortisone is the preferred replacement agent.
20. [CASE 5 — QUESTION 4]
Eighteen months after surgery Ms. C.B.'s HPA axis has fully recovered confirmed by a normal ACTH stimulation test. Hydrocortisone has been discontinued. Her BP remains 122/76 mmHg on no antihypertensive medications. Her HbA1c is 5.9% and she has lost a total of 14 kg. However, she has developed new-onset osteopenia on DEXA scan (T-score -1.8 at the lumbar spine). Which of the following most accurately describes the relationship between her prior hypercortisolemia and the osteopenia?
A) The osteopenia is unrelated to her prior Cushing disease — she is 44 years old and perimenopausal bone loss is the most likely explanation; cortisol excess does not affect bone density
B) The osteopenia is a direct consequence of her prior hypercortisolemia — cortisol excess causes bone loss through multiple mechanisms: suppression of osteoblast activity and promotion of osteoblast apoptosis, stimulation of RANK-L mediated osteoclast activity, reduction of intestinal calcium absorption through glucocorticoid antagonism of vitamin D action, increased renal calcium excretion, and suppression of gonadotropins reducing sex steroid levels that normally maintain bone density; bone loss from Cushing syndrome may not fully reverse after cure and requires assessment and potentially pharmacological management
C) The osteopenia will fully reverse within 6 months of cortisol normalization — bone density always returns to baseline after Cushing disease cure because osteoblast suppression is completely reversible within this timeframe
D) The osteopenia indicates that her Cushing disease has recurred — cortisol excess is the only explanation for bone loss at her age and a repeat 24-hour urinary free cortisol should be obtained before evaluating the osteopenia further
E) No pharmacological management of the osteopenia is needed — a T-score of -1.8 represents normal bone density for her age and no intervention is indicated until the T-score falls below -2.5
ANSWER: B
Rationale:
Hypercortisolemia causes significant bone loss through multiple complementary mechanisms — direct suppression of osteoblast proliferation and induction of osteoblast apoptosis reduces bone formation; upregulation of RANK-L stimulates osteoclast-mediated bone resorption; glucocorticoid antagonism of intestinal vitamin D-dependent calcium absorption and increased renal calcium wasting reduce calcium availability for bone mineralization; suppression of the hypothalamic-pituitary-gonadal axis reduces estrogen and testosterone, which normally maintain bone density; the result is trabecular bone loss disproportionate to age-related osteoporosis; after cure, bone density improves but may not fully recover to pre-disease levels, particularly with prolonged or severe prior exposure; her osteopenia warrants calcium and vitamin D supplementation and consideration of bisphosphonate therapy depending on fracture risk assessment.
Option A: Option A is incorrect — cortisol excess is a well-established and potent cause of secondary osteoporosis; perimenopausal bone loss alone does not explain the degree of bone loss at 44 in the context of prior Cushing disease.
Option C: Option C is incorrect — bone recovery after Cushing disease cure occurs gradually over years and is often incomplete; full return to baseline within 6 months is not expected.
Option D: Option D is incorrect — osteopenia after treated Cushing disease is an expected sequela, not a marker of recurrence; recurrence should be evaluated biochemically with cortisol measurement, not assumed from osteopenia alone.
Option E: Option E is incorrect — a T-score of -1.8 represents osteopenia (between -1.0 and -2.5), not normal bone density; it warrants evaluation and intervention; the threshold for pharmacological treatment with bisphosphonates depends on fracture risk assessment (FRAX score), not T-score alone, but this patient's prior glucocorticoid excess is a recognized risk factor that lowers the treatment threshold.
CASE 6
Mr. A.W. is a 61-year-old man with known hypertension on lisinopril 20 mg and hydrochlorothiazide 25 mg who presents to the emergency department with BP 218/128 mmHg and a severe headache that began 2 hours ago. His wife reports he ran out of his medications 5 days ago. Neurological examination is normal. Fundoscopy shows arteriovenous nicking and mild arteriolar narrowing but no hemorrhages, exudates, or papilledema. Creatinine is 1.2 mg/dL (baseline 1.1 mg/dL). ECG shows LVH by voltage criteria. Urinalysis is normal. CT head is normal.
21. [CASE 6 — QUESTION 1]
Which of the following most accurately classifies Mr. A.W.'s presentation and guides the urgency of BP lowering?
A) He has a hypertensive emergency requiring immediate IV antihypertensive therapy targeting a BP reduction of 25% within the first hour — any BP above 180/120 mmHg constitutes a hypertensive emergency regardless of symptoms or end-organ examination
B) The LVH on ECG confirms hypertensive emergency because LVH is a form of acute cardiac target organ damage requiring IV antihypertensive therapy
C) He has a hypertensive urgency — BP is severely elevated at 218/128 mmHg but there is no evidence of acute end-organ damage (no neurological deficits, no retinal hemorrhages or papilledema, creatinine only minimally above baseline, normal urinalysis, normal CT head); the distinction between urgency and emergency is determined by the presence or absence of acute target organ damage, not the absolute BP level; management is gradual oral BP lowering over 24–48 hours targeting a 20–25% reduction, not immediate IV therapy
D) He has hypertensive emergency because his BP exceeds 200 mmHg systolic — the threshold for emergency classification is any BP above 200/120 mmHg regardless of clinical findings
E) The normal CT head excludes hypertensive emergency — neuroimaging is the definitive test for end-organ damage in severe hypertension and a normal result allows safe discharge without treatment
ANSWER: C
Rationale:
The critical distinction between hypertensive emergency and hypertensive urgency is the presence or absence of acute end-organ damage — not the absolute BP level; Mr. A.W. has severely elevated BP but a careful examination reveals no acute end-organ damage: neurological exam is normal (no hypertensive encephalopathy or stroke), fundoscopy shows chronic hypertensive changes (AV nicking, arteriolar narrowing) but no acute findings (no hemorrhages, exudates, or papilledema), creatinine is minimally elevated from baseline consistent with chronic changes rather than acute hypertensive nephropathy, urinalysis is normal, and CT head is normal; hypertensive urgency is managed with gradual oral BP lowering over 24–48 hours; the AV nicking and LVH reflect chronic hypertensive target organ damage.
Option A: Option A is incorrect — a 25% BP reduction in the first hour is the target for hypertensive emergency, not urgency; applying emergency protocols to urgency risks overly rapid BP reduction causing cerebral hypoperfusion.
Option B: Option B is incorrect — LVH by ECG voltage criteria is a marker of chronic hypertensive cardiac remodeling, not acute end-organ damage; it is present in this patient's chronic hypertension history and does not convert urgency to emergency.
Option D: Option D is incorrect — BP level alone does not determine emergency vs urgency classification; the critical determinant is acute end-organ damage; patients with BP above 200/120 mmHg without acute organ damage are classified as urgency, not emergency.
Option E: Option E is incorrect — CT head evaluates for neurological end-organ damage specifically; a normal CT does not exclude other forms of end-organ damage (retinal, renal, cardiac) and does not authorize discharge without treatment; it is one component of the evaluation.
22. [CASE 6 — QUESTION 2]
Mr. A.W. is appropriately classified as hypertensive urgency. He is restarted on lisinopril 20 mg and hydrochlorothiazide 25 mg and given clonidine 0.2 mg orally in the ED. His BP at 2 hours is 188/114 mmHg. At 6 hours it is 172/106 mmHg. He is discharged with instructions to take his medications daily and follow up in 48 hours. At the 48-hour follow-up his BP is 158/96 mmHg. His physician wants to add a third agent. Which of the following most accurately identifies the most appropriate addition given his clinical profile?
A) Hydralazine should be added as a third agent because its direct vasodilator mechanism complements the existing ACE inhibitor and diuretic without pharmacological overlap
B) Clonidine should be prescribed as a standing daily medication as the third agent because it effectively lowered his BP in the ED and this confirms that central sympatholysis is his most effective mechanism of BP control
C) A beta-blocker should be the third agent added because his LVH on ECG indicates he has had a prior MI that was not detected and beta-blockers are indicated for post-MI LVH
D) Spironolactone should be the third agent because resistant hypertension always has a primary aldosteronism component that should be empirically treated with a mineralocorticoid receptor antagonist before any other third-line agent is tried
E) Amlodipine 5 mg should be added — a dihydropyridine calcium channel blocker is evidence-based as a third agent in resistant or difficult-to-control hypertension, complementing the ACE inhibitor (which reduces RAAS-mediated vasoconstriction) and the thiazide diuretic (which reduces volume); the combination of ACE inhibitor, CCB, and thiazide diuretic is supported by the ACCOMPLISH trial as superior to ACE inhibitor plus thiazide for cardiovascular outcomes in high-risk hypertensive patients
ANSWER: E
Rationale:
Amlodipine is the most appropriate third agent in this patient — the combination of ACE inhibitor, calcium channel blocker, and thiazide diuretic (ACE+CCB+thiazide) is the evidence-based backbone of hypertension management in patients requiring three agents; the ACCOMPLISH trial demonstrated that the ACE inhibitor plus CCB combination was superior to ACE inhibitor plus thiazide for cardiovascular outcomes in high-risk hypertensive patients, though the NICE guidelines support the triple combination; this regimen provides complementary mechanisms (RAAS blockade, vasodilation, volume reduction) without pharmacological redundancy.
Option A: Option A is incorrect — hydralazine causes reflex tachycardia, fluid retention requiring diuretic optimization, and has an inconvenient thrice-daily dosing schedule; it is not a preferred third agent in modern hypertension management when CCBs are available and better tolerated.
Option C: Option C is incorrect — LVH on ECG in a hypertensive patient reflects chronic pressure overload remodeling, not a prior MI; inferring an undetected MI from voltage criteria for LVH is not clinically valid; beta-blockers are not first-choice antihypertensives for uncomplicated hypertension.
Option D: Option D is incorrect — empirical spironolactone for all resistant hypertension without biochemical evidence of primary aldosteronism is not the standard approach as a third-line agent; in true resistant hypertension on three agents, spironolactone has evidence as a fourth agent (PATHWAY-2), but this patient is on two agents and the appropriate third-line addition is a CCB.
Option B: Option B is incorrect — clonidine's acute ED effect reflects its rapid onset; it is not an appropriate standing long-term antihypertensive as a third agent due to rebound hypertension with missed doses, CNS side effects, and lack of cardiovascular outcome data.
23. [CASE 6 — QUESTION 3]
Amlodipine 5 mg is added. At 3-month follow-up Mr. A.W.'s BP is 134/82 mmHg and he is tolerating all three medications well. He develops new bilateral ankle edema. He has no signs of heart failure — his JVP is normal, lungs are clear, and echocardiogram shows preserved EF with no new wall motion abnormalities. Which of the following most accurately explains the etiology of the ankle edema and guides management?
A) The ankle edema represents new-onset heart failure from amlodipine's negative inotropic effect — amlodipine directly suppresses myocardial contractility and should be discontinued immediately and replaced with a beta-blocker
B) The ankle edema is caused by amlodipine-induced precapillary arteriolar dilation without equivalent venodilation — dihydropyridine CCBs dilate arterioles (reducing afterload) but have minimal effect on venous capacitance vessels; the resulting increase in capillary hydrostatic pressure in the dependent lower extremities causes fluid transudation into the interstitium; this is not cardiac edema or sodium retention; dose reduction of amlodipine or addition of an ACE inhibitor (already present in this regimen) partially counteracts CCB edema through venodilation; the edema can also be managed with leg elevation and compression stockings; if intolerable, reducing the amlodipine dose or switching to a CCB with more balanced arteriovenous dilation may be considered
C) The ankle edema is caused by hydrochlorothiazide-induced hypoalbuminemia from urinary protein loss — thiazide diuretics cause nephrotic-range proteinuria that reduces oncotic pressure and causes dependent edema
D) Adding more diuretic (furosemide) is the correct management for amlodipine-induced ankle edema — loop diuretics directly remove the interstitial fluid causing the edema and resolve the problem without any change to the amlodipine dose
E) The ankle edema indicates the amlodipine dose must be reduced to 2.5 mg immediately — at 5 mg amlodipine always causes clinically significant edema and the dose should never exceed 2.5 mg in any patient
ANSWER: B
Rationale:
Amlodipine-induced peripheral edema is a class effect of dihydropyridine CCBs caused by selective arteriolar dilation without equivalent venodilation — the resulting imbalance increases capillary hydrostatic pressure in dependent tissues, causing fluid transudation into the interstitium; this is not cardiac edema (confirmed by the normal JVP, clear lungs, and preserved EF) and is not sodium-mediated; RAAS inhibitors (ACE inhibitors or ARBs) partially counteract this mechanism through venodilation and are already present in his regimen; management options include leg elevation, compression stockings, dose reduction if BP allows, or switching CCBs; adding more diuretic does not address the underlying hemodynamic mechanism and risks volume depletion.
Option A: Option A is incorrect — amlodipine is a dihydropyridine CCB with minimal negative inotropic effect at therapeutic doses; it does not cause heart failure through myocardial suppression; the edema is not cardiac; this is a safe and commonly used agent in heart failure with preserved EF.
Option C: Option C is incorrect — hydrochlorothiazide does not cause nephrotic-range proteinuria or hypoalbuminemia; thiazide-induced hypoalbuminemia is not a recognized mechanism of edema.
Option D: Option D is incorrect — adding furosemide treats the interstitial edema symptomatically through sodium and water excretion but does not address the underlying hemodynamic mechanism of increased capillary hydrostatic pressure; it risks hypokalemia, volume depletion, and electrolyte disturbance without a pharmacological rationale specific to CCB edema.
Option E: Option E is incorrect — not all patients develop clinically significant edema at 5 mg amlodipine; the edema is dose-dependent but a fixed rule against doses above 2.5 mg is not appropriate; clinical response and tolerability guide dosing decisions.
24. [CASE 6 — QUESTION 4]
Mr. A.W. manages the ankle edema with compression stockings and it becomes tolerable. His BP remains well controlled at 128/78 mmHg. He asks his physician about his long-term cardiovascular risk and what BP target he should be aiming for. His 10-year ASCVD risk is calculated at 18%. He has no diabetes and no CKD. Which of the following most accurately describes the evidence-based BP target for Mr. A.W. and the trial evidence supporting it?
A) The BP target for all hypertensive patients regardless of risk is below 140/90 mmHg — this is the universal threshold supported by all major guidelines and more intensive targets have not been shown to provide additional benefit in any population
B) The intensive BP target of below 120/80 mmHg demonstrated in SPRINT should be applied to Mr. A.W. immediately — more aggressive lowering than his current 128/78 mmHg is required to maximize cardiovascular benefit based on the SPRINT intensive arm results
C) The BP target should be below 150/90 mmHg because he is over 60 years old — the JNC 8 guideline recommended a relaxed target of below 150/90 mmHg for patients aged 60 and older regardless of cardiovascular risk, and this recommendation supersedes all subsequent trial evidence
D) BP targets are not evidence-based in patients with LVH — LVH represents irreversible structural cardiac change that does not respond to BP lowering; the target should be determined by symptom control rather than a specific numerical goal
E) A BP target of below 130/80 mmHg is appropriate for Mr. A.W. given his high cardiovascular risk (10-year ASCVD risk 18%, LVH, prior hypertensive urgency) — the SPRINT trial demonstrated that a systolic BP target of below 120 mmHg (intensive) compared to below 140 mmHg (standard) significantly reduced cardiovascular events and all-cause mortality in high-risk non-diabetic patients; the 2017 ACC/AHA guidelines incorporated this evidence to define stage 2 hypertension and recommend a below 130/80 mmHg target for high-risk patients; his current BP of 128/78 mmHg is within this target range
ANSWER: E
Rationale:
The 2017 ACC/AHA guidelines recommend a BP target of below 130/80 mmHg for patients with hypertension and high cardiovascular risk — defined as 10-year ASCVD risk of 10% or greater, established CVD, CKD, or diabetes; Mr. A.W. has an 18% 10-year ASCVD risk placing him firmly in the high-risk category; the SPRINT trial (Systolic Blood Pressure Intervention Trial) demonstrated that targeting systolic BP below 120 mmHg versus below 140 mmHg in high-risk non-diabetic patients significantly reduced major adverse cardiovascular events and all-cause mortality; his current BP of 128/78 mmHg is within the guideline-recommended target and represents appropriate BP control; further intensification to below 120 mmHg is not required.
Option A: Option A is incorrect — while below 140/90 mmHg was the historical universal target, contemporary guidelines differentiate targets based on cardiovascular risk; high-risk patients benefit from the below 130/80 mmHg target.
Option C: Option C is incorrect — JNC 8's relaxed target of below 150/90 mmHg for patients over 60 was controversial and was not universally adopted; subsequent SPRINT data and the 2017 ACC/AHA guidelines superseded this recommendation for high-risk patients; applying the relaxed target to this high-risk patient would be suboptimal.
Option D: Option D is incorrect — LVH does regress with effective BP lowering; this is well established and is one of the arguments for achieving adequate BP control; it is not irreversible.
Option B: Option B is incorrect — while SPRINT demonstrated cardiovascular benefit at systolic below 120 mmHg, this intensive target came with increased adverse events including AKI, syncope, and electrolyte abnormalities; the guideline recommendation is below 130/80 mmHg for high-risk patients, not below 120/80 mmHg as a universal intensive target; his current BP is within the appropriate target range.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.